pemigatinib
Researchers are planning a clinical trial after four metastatic FGFR2 fusion-positive pancreatic cancer patients responded to FGFR-directed therapy.
Incyte's Pemazyre Approved in Japan for FGFR1-Positive Rare Blood Cancers
The approval in Japan and the FDA's approval last year in the same indication are based on results from a Phase II trial in patients whose cancers bear FGFR1 fusions.
Relay Therapeutics' Selective FGFR2 Inhibitor Yields 'Remarkable' Responses in Bile Duct Cancer
Premium
Oncologists at ESMO said they're eager to see mature data on the drug's impact on duration of response and overall survival in patients with FGFR inhibitor-naïve FGFR2-altered bile duct cancer.
Incyte's Pemazyre Nets FDA Approval for Rare Blood Cancer
The approval makes Pemazyre the first targeted treatment available for FGFR1-rearranged relapsed or refractory myeloid/lymphoid neoplasms.
NICE Recommends Incyte's Pemazyre for FGFR2-Positive Bile Duct Cancer
The drug was approved in the UK for previously treated patients with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement.